Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Multiple myeloma and its treatment contribute to increased platelet reactivity.

Mitchell JL. et al, (2023), Platelets, 34

Extended exposure to low doses of azacitidine induces differentiation of leukemic stem cells through activation of myeloperoxidase.

Jeyaraju DV. et al, (2023), Haematologica

Luspatercept stimulates erythropoiesis, increases iron utilization, and redistributes body iron in transfusion-dependent thalassemia

Thakurta A., (2023), American journal of hematology

Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML-001 trial.

Menezes DL. et al, (2023), Br j haematol, 201, 1129 - 1143

High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma.

Samur MK. et al, (2023), Blood, 141, 1724 - 1736

The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM.

Stong N. et al, (2023), Blood, 141, 1574 - 1583

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma.

Ansari-Pour N. et al, (2023), Blood, 141, 620 - 633

Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma.

Kurata K. et al, (2023), Blood cancer j, 13

Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma.

Kurata K. et al, (2023), Blood cancer j, 13

Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma.

Gooding S. et al, (2022), Blood, 140, 1816 - 1821

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine.

Döhner H. et al, (2022), Blood, 140, 1674 - 1685

Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma.

Sudha P. et al, (2022), Clin cancer res, 28, 2854 - 2864

Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1.

Wu W. et al, (2022), Blood, 139, 2024 - 2037

The Next Frontier: Translational Development of Ubiquitination, SUMOylation, and NEDDylation in Cancer.

Pellegrino NE. et al, (2022), Int j mol sci, 23

Biomarker analysis to support dose optimization of iberdomide (IBER) as monotherapy and in combination with standard of care treatments for multiple myeloma from a phase 1/2 trial

Amatangelo M. et al, (2022), Clinical lymphoma myeloma & leukemia, 22, S162 - S162

Development of a mass cytometry-based toolkit to investigate myeloma therapeutic responses ex vivo

Gooding S. et al, (2022), Clinical lymphoma myeloma & leukemia, 22, S71 - S71

Iberdomide induces activation and proliferation of innate and adaptive immune cell subsets in the tumor microenvironment of relapsed/refractory myeloma patients

Van Oekelen O. et al, (2022), Clinical lymphoma myeloma & leukemia, 22, S86 - S87

Multiple Myeloma Patient Tumors With High Levels of Cereblon Exon-10 Deletion Splice Variant Upregulate Clinically Targetable Pro-Inflammatory Cytokine Pathways.

Karagoz K. et al, (2022), Front genet, 13

Suppression of Myeloid Cell-Derived Proinflammatory Cytokines with Celmod Agents: Implications for CRS with T-Cell Engagers (TCEs)

Jeyaraju DV. et al, (2022), Blood, 140, 7070 - 7071

Integrative multi-omics identifies high risk multiple myeloma subgroup associated with significant DNA loss and dysregulated DNA repair and cell cycle pathways.

Ortiz-Estévez M. et al, (2021), Bmc med genomics, 14

Load More

1
2
3
4
5

Include forthcoming?